메뉴 건너뛰기




Volumn 98, Issue 13, 2006, Pages 904-910

Effect of factor V Leiden and prothrombin G20210→ A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENINE; BLOOD CLOTTING FACTOR 5 LEIDEN; GENOMIC DNA; GUANINE; PLACEBO; PROTHROMBIN; TAMOXIFEN;

EID: 33745776681     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj262     Document Type: Article
Times cited : (55)

References (26)
  • 1
    • 0032537990 scopus 로고    scopus 로고
    • Tamoxifen for prevention of breast cancer
    • Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin W, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1371-1388
    • Fisher, B.1    Costantino, J.P.2    Wickerham, D.L.3    Redmond, C.K.4    Kavanah, M.5    Cronin, W.6
  • 2
    • 0030992308 scopus 로고    scopus 로고
    • Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden
    • Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997;79:2024-7.
    • (1997) Cancer , vol.79 , pp. 2024-2027
    • Weitz, I.C.1    Israel, V.K.2    Liebman, H.A.3
  • 4
    • 0141904693 scopus 로고    scopus 로고
    • Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer
    • Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588-93.
    • (2003) J Clin Oncol , vol.21 , pp. 3588-3593
    • Duggan, C.1    Marriott, K.2    Edwards, R.3    Cuzick, J.4
  • 5
    • 0025981392 scopus 로고
    • Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
    • Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
    • (1991) J Clin Oncol , vol.9 , pp. 286-294
    • Saphner, T.1    Tormey, D.C.2    Gray, R.3
  • 6
    • 0029850530 scopus 로고    scopus 로고
    • A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
    • Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
    • (1996) Blood , vol.88 , pp. 3698-3703
    • Poort, S.R.1    Rosendaal, F.R.2    Reitsma, P.H.3    Bertina, R.M.4
  • 7
    • 0028098210 scopus 로고
    • Resistance to activated protein C as a basis for venous thrombosis
    • Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
    • (1994) N Engl J Med , vol.330 , pp. 517-522
    • Svensson, P.J.1    Dahlback, B.2
  • 8
    • 1842290346 scopus 로고    scopus 로고
    • Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis
    • Dahlback B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483-8.
    • (1997) Thromb Haemost , vol.78 , pp. 483-488
    • Dahlback, B.1
  • 10
    • 0028029477 scopus 로고
    • Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
    • Vandenbroucke JP, Koster T, Briet D, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
    • (1994) Lancet , vol.344 , pp. 1453-1457
    • Vandenbroucke, J.P.1    Koster, T.2    Briet, D.3    Reitsma, P.H.4    Bertina, R.M.5    Rosendaal, F.R.6
  • 11
    • 0027428481 scopus 로고
    • Anticoagulant protein C pathway defective in majority of thrombophilic patients
    • Griffin JH, Evatt B, Wideman C, Fernadez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82: 1989-93.
    • (1993) Blood , vol.82 , pp. 1989-1993
    • Griffin, J.H.1    Evatt, B.2    Wideman, C.3    Fernadez, J.A.4
  • 12
    • 0028931717 scopus 로고
    • High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
    • Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
    • (1995) Blood , vol.85 , pp. 1504-1508
    • Rosendaal, F.R.1    Koster, T.2    Vandenbroucke, J.P.3    Reitsma, P.H.4
  • 14
    • 0028810738 scopus 로고
    • World distribution of factor V Leiden
    • Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
    • (1995) Lancet , vol.346 , pp. 1133-1134
    • Rees, D.C.1    Cox, M.2    Clegg, J.B.3
  • 15
    • 0036788617 scopus 로고    scopus 로고
    • Retrospective assessment of hypercoagulability in breast cancer prevention trial
    • Abramson N, Aster RH. Retrospective assessment of hypercoagulability in breast cancer prevention trial. J Clin Oncol 2002;20:4133-4.
    • (2002) J Clin Oncol , vol.20 , pp. 4133-4134
    • Abramson, N.1    Aster, R.H.2
  • 16
    • 0032521251 scopus 로고    scopus 로고
    • Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood
    • Gomez E, van der Poel SC, Jansen JH, van der Reijden BA, Lowenberg B. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood 1998;91:2208-9.
    • (1998) Blood , vol.91 , pp. 2208-2209
    • Gomez, E.1    van der Poel, S.C.2    Jansen, J.H.3    van der Reijden, B.A.4    Lowenberg, B.5
  • 17
  • 18
    • 0026562206 scopus 로고
    • Applications of crude incidence curves
    • Korn J, Dorey FJ. Applications of crude incidence curves. Stat Med 1992; 11:813-29.
    • (1992) Stat Med , vol.11 , pp. 813-829
    • Korn, J.1    Dorey, F.J.2
  • 19
    • 33845248846 scopus 로고
    • Inference for events with dependent risks in multiple endpoint studies
    • Pepe MS. Inference for events with dependent risks in multiple endpoint studies. J Am Stat Assoc 1991;86:770-8.
    • (1991) J Am Stat Assoc , vol.86 , pp. 770-778
    • Pepe, M.S.1
  • 21
    • 0035176945 scopus 로고    scopus 로고
    • Venous thromboembolism and hormone replacement therapy
    • Mannucci PM. Venous thromboembolism and hormone replacement therapy. Eur J Intern Med 2001;12:478-83.
    • (2001) Eur J Intern Med , vol.12 , pp. 478-483
    • Mannucci, P.M.1
  • 22
    • 0031868669 scopus 로고    scopus 로고
    • Oral contraceptives and venous thromboembolism. A case-control study
    • Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998;57:291-301.
    • (1998) Contraception , vol.57 , pp. 291-301
    • Lidegaard, O.1    Edstrom, B.2    Kreiner, S.3
  • 23
    • 0034595197 scopus 로고    scopus 로고
    • Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study
    • Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med 2000;132:689-96.
    • (2000) Ann Intern Med , vol.132 , pp. 689-696
    • Grady, D.1    Wenger, N.K.2    Herrington, D.3    Khan, S.4    Furberg, C.5    Hunninghake, D.6
  • 24
    • 0035489312 scopus 로고    scopus 로고
    • Hypercoagulability: Clinical assessment and treatment
    • Abramson N, Abramson S. Hypercoagulability: Clinical assessment and treatment. South Med J 2001;94:1013-20.
    • (2001) South Med J , vol.94 , pp. 1013-1020
    • Abramson, N.1    Abramson, S.2
  • 25
    • 0032190251 scopus 로고    scopus 로고
    • Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families
    • Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 1998;92: 2353-8.
    • (1998) Blood , vol.92 , pp. 2353-2358
    • Martinelli, I.1    Mannucci, P.M.2    De Stefano, V.3    Taioli, E.4    Rossi, V.5    Crosti, F.6
  • 26
    • 0037219744 scopus 로고    scopus 로고
    • Effect of tamoxifen on venous thrombosis risk factors in women without cancer
    • The Breast Cancer Prevention Trial
    • Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The Breast Cancer Prevention Trial. Br J Haematol 2003;120:109-16.
    • (2003) Br J Haematol , vol.120 , pp. 109-116
    • Cushman, M.1    Costantino, J.P.2    Bovill, E.G.3    Wickerham, D.L.4    Buckley, L.5    Roberts, J.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.